{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:32:47Z","timestamp":1791829967560,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Hengrui Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04053-7","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:10:21Z","timestamp":1746799821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaolin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houbao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiwu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"9360","key":"4053_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","volume":"361","author":"H Gr\u00f6nberg","year":"2003","unstructured":"Gr\u00f6nberg H. Prostate cancer epidemiology. The Lancet. 2003;361(9360):859\u201364.","journal-title":"The Lancet"},{"issue":"3","key":"4053_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clgc.2018.01.005","volume":"16","author":"M Claps","year":"2018","unstructured":"Claps M, Petrelli F, Caffo O, Amoroso V, Roca E, Mosca A, et al. Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis. Clin Genitourin Cancer. 2018;16(3):165-75.e2.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"4053_CR3","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1055-9965.EPI-04-0715","volume":"14","author":"JK Parsons","year":"2005","unstructured":"Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2257\u201360.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"4053_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/02841860510029743","volume":"44","author":"JE Damber","year":"2005","unstructured":"Damber JE. Endocrine therapy for prostate cancer. Acta Oncol. 2005;44(6):605\u20139.","journal-title":"Acta Oncol"},{"issue":"1","key":"4053_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","volume":"168","author":"C Huggins","year":"2002","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9\u201312.","journal-title":"J Urol"},{"issue":"5","key":"4053_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41585-022-00686-y","volume":"20","author":"R Kumar","year":"2023","unstructured":"Kumar R, Sena LA, Denmeade SR, Kachhap S. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. Nat Rev Urol. 2023;20(5):265\u201378.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"4053_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/ncpuro1237","volume":"5","author":"AHM Reid","year":"2008","unstructured":"Reid AHM, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610\u201320.","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"4053_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351.","journal-title":"N Engl J Med"},{"key":"4053_CR9","unstructured":"U.S. Food and Drug Administration. 2011 Notifications. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/2011-notifications."},{"issue":"12","key":"4053_CR10","first-page":"4453","volume":"63","author":"T Solymosi","year":"2018","unstructured":"Solymosi T, T\u00f3th F, Orosz J, Basa-D\u00e9nes O, Angi R, Jord\u00e1n T, et al. Solubility measurements at 296 and 310 K and physicochemical characterization of abiraterone and abiraterone acetate. J Chem Eng Data. 2018;63(12):4453\u20138.","journal-title":"J Chem Eng Data"},{"issue":"3","key":"4053_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00280-018-3754-x","volume":"83","author":"C Wang","year":"2019","unstructured":"Wang C, Hu C, Gao D, Zhao Z, Chen X, Hu X, et al. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2019;83(3):509\u201317.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"4053_CR12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/jcph.564","volume":"55","author":"KN Chi","year":"2015","unstructured":"Chi KN, Spratlin J, Kollmannsberger C, North S, Pankras C, Gonzalez M, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015;55(12):1406\u201314.","journal-title":"J Clin Pharmacol"},{"key":"4053_CR13","unstructured":"U.S. Food and Drug Administration. ZYTIGA\u00ae Highlights of Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202379s007lbl.pdf."},{"issue":"4","key":"4053_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2147\/DDDT.S339305","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev Boris Y, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"key":"4053_CR15","doi-asserted-by":"crossref","unstructured":"Feng Z, Liu Y, Kuang Y, Yang S, Li J, Ye L, et al. Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets. Drug Des Devel Ther. 2022 2022; 16:[3-12 pp.]. Available from: http:\/\/europepmc.org\/abstract\/MED\/35018094.https:\/\/www.dovepress.com\/getfile.php?fileID=77291.10.2147\/DDDT.S339305.https:\/\/europepmc.org\/articles\/PMC8740623.https:\/\/europepmc.org\/articles\/PMC8740623?pdf=render.","DOI":"10.2147\/DDDT.S339305"},{"issue":"7","key":"4053_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148\u201359.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4053_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"2","key":"4053_CR18","doi-asserted-by":"publisher","first-page":"81e9","DOI":"10.1016\/j.urolonc.2017.10.018","volume":"36","author":"CA Stein","year":"2018","unstructured":"Stein CA, Levin R, Given R, Higano CS, Nemeth P, Bosch B, et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. Urol Oncol: Semin Orig Invest. 2018;36(2):81e9-.e16.","journal-title":"Urol Oncol: Semin Orig Invest."},{"issue":"2","key":"4053_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/pcan.2014.8","volume":"17","author":"CJ Ryan","year":"2014","unstructured":"Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014;17(2):192\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"4053_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.120.265868","volume":"374","author":"EJY Cheong","year":"2020","unstructured":"Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, et al. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone redefines its kinetic selectivity and dosing regimen. J Pharmacol Exp Ther. 2020;374(3):438\u201351.","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"4053_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","volume":"36","author":"RZ Szmulewitz","year":"2018","unstructured":"Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, et al. Prospective international randomized phase ii study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36(14):1389\u201395.","journal-title":"J Clin Oncol"},{"key":"4053_CR22","unstructured":"YONSA\u00ae Highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210308s000lbl.pdf."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04053-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04053-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04053-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:10:23Z","timestamp":1746799823000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04053-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4053"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04053-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and all amendments were approved by the Ethical Committee of Fudan University Shanghai Cancer Center (2012228\u201315 -\u20092101 A). The study was conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and the local laws and regulations. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Bin Zheng and Guoqiang Chen received research grants from Hengrui; Huan Wang and Quanren Wang are employees of Hengrui. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}